P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia

Neurological Sciences

Volumn 26, Issue 6, 2006, Pages 435-437

  Paci, C ^a   Gobbato, R ^a   Carboni, T ^a   Sanguigni, S ^a   Santone, A ^b   Curatola, L ^a  

^a Madonna del Soccorso Hospital   (Italy)

^b Department of Prevention ^*  (Italy)

Author keywords

Donepezil; P300; Vascular dementia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; NEUROTRANSMITTER; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; EVOKED AUDITORY RESPONSE; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATHOGENESIS; TREATMENT DURATION;

ACOUSTIC STIMULATION; AGED; DEMENTIA, VASCULAR; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES;

EID: 33645680819     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0528-8     Document Type: Article

References (15)

1. Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13[Suppl 3]:115-123
2. Wilkinson DG (1999) The pharmacology of donepezil: A new treatment of Alzheimer's disease. Expert Opin Pharmacother 1:121-135
3. Mendez MF, Younesi FL, Perryman KM (1999) Use of donepezil for vascular dementia: Preliminary clinical experience. J Neuropsychiatry Clin Neurosci 11:268-270
4. Kumar V, Anand R, Messina J, Hartman R, Veach J (2000) An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur Neurol 7:159-169
5. Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 359:1283-1290
6. Erkinjuntti T, Roman G, Gauthier S (2004) Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 226:63-66
7. Erkinjuntti T, Roman G, Gauthier S et al (2004) Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35:1010-1017
8. Kurz AF, Erkinjuntti T, Small GW et al (2003) Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 10:633-640
9. Moretti R, Torre P, Antonello RM et al (2004) Rivastigmine in vascular dementia. Expert Opin Pharmacother 5:1399-1410
10. Wilkinson D, Doody R, Helme R et al (2003) Donepezil in vascular dementia. Neurology 61:479-486
11. Katada E, Sato K, Sawaki A et al (2003) Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 16:39-43
12. Onofrj M, Thomas A, Luciano AL et al (2002) Donepezil versus vitamin E in Alzheimer's disease: Part 2 mild versus moderate- severe Alzheimer's disease. Clin Neuropharmacol 25:207-215
13. Roman GC, Tatemichi TK, Erkinjutti T et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of NINDS-AIREN International Work-shop. Neurology 43:250-260
14. Folstein MF, Folstein SE, McHugh PR (1975) Mini Mental State: A practice method for grading the cognitive state of patients for clinicians. J Psychiatr Res 12:189-198
15. Rosen WG, Mohs RG, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatr 141:1356-1364